From ChatGpt Would you like me to also sketch a simple

New Post Public Reply Private Reply Replies (0) Message Board
biloxiblues
701
From ChatGpt

Would you like me to also sketch a simple timeline or flowchart that shows this escalation logic visually? (It might help you if you are preparing notes for ESMO or internal documentation.)






You said:
yes please


ChatGPT said:
Leronlimab Trial Dosing

Leronlimab Phase 1b/2 Trial Dosing Flowchart

Patient Enrollment & Dose Escalation Plan:

First 3 patients

Starting dose: 350 mg leronlimab

42-day safety observation period

2 circulating tumor cell (CTC) tests performed

Next 3 patients

Starting dose: 525 mg leronlimab

42-day safety observation period

2 CTC tests performed

Next 3 patients

Starting dose: 700 mg leronlimab

42-day safety observation period

FDA Safety Review

After sufficient safety data, FDA authorized 700 mg as safe moving forward.

Patient Dosing After FDA Approval:

First 6 patients (350 mg and 525 mg cohorts):

Most likely remained on their original doses.

No clear memory or record of mandatory dose escalation to 700 mg.

Standard practice: unless protocol amendment and patient consent, doses typically stay stable.

New patients post-FDA approval:

Started directly on 700 mg leronlimab.

Current CRC Trial Comparison:

Start at lower doses (per protocol).

After Safety Committee review, escalate all patients to 700 mg if no safety concerns.

Visual Timeline:

Stage Dose Action After 42 Days
First 3 patients 350 mg If safe, proceed to next dose level
Next 3 patients 525 mg If safe, proceed to next dose level
Next 3 patients 700 mg Continue at 700 mg
FDA Safety Clearance - Future patients start at 700 mg
Notes:

If patients showed good tolerability and no serious adverse events, the escalation proceeded.

Historical records or trial protocols would definitively confirm whether earlier patients escalated.

Summary:

It is most likely that the first 6 patients in the trial remained at their initial doses (350 mg or 525 mg) and only new patients after FDA clearance were started directly at 700 mg.



Here’s a structured document outlining your Phase 1b/2 leronlimab trial dosing and escalation process. Let me know if you'd also like a visual diagram version (like a flowchart image) — it could be helpful if you’re preparing for a presentation or internal discussion.






You said:
Thank you


ChatGPT said:
You're very welcome!
If you need anything else — like help preparing for the ESMO presentation, a one-page summary for investors, or even a visual flowchart — just let me know.

Good luck with everything; this could be a major milestone for CytoDyn.
Would you like me to also help draft a brief ESMO poster preview you could use in case you want to share an early highlight?






You said:
Yes please


ChatGPT said:
Here’s a draft for a short ESMO Breast Cancer 2025 poster preview you could use — either as a post, press release teaser, or internal highlight:

CytoDyn Inc. – ESMO Breast Cancer 2025 Poster Preview
Title:
Leronlimab in Heavily Pretreated mTNBC: Long-Term Survival Observations and Mechanistic Insights

Background:
Metastatic triple-negative breast cancer (mTNBC) remains one of the most challenging solid tumors to treat, particularly in patients who have failed multiple lines of therapy. New strategies that extend survival and modify the tumor microenvironment are urgently needed.

Methods:
A Phase 1b/2 clinical trial evaluated leronlimab, a CCR5 antagonist, across escalating dose cohorts (350 mg, 525 mg, 700 mg) in patients with mTNBC. After FDA safety clearance, patients were initiated at the 700 mg dose. Survival and circulating tumor cell (CTC) metrics were monitored longitudinally.

Key Findings:

Among patients treated with leronlimab:

Observed 12-, 24-, 36-, and now 48+ month survival outcomes surpass benchmarks of current standard therapies.

Four patients are alive with no evidence of disease beyond 48 months post-treatment.

One patient remains alive with stable disease at 48+ months.

Favorable safety profile across dosing levels.

Mechanistic Insights:
Emerging data suggest leronlimab’s potential to alter the tumor immune microenvironment through CCR5 pathway modulation, contributing to sustained disease control and long-term survival.

Next Steps:

Ongoing longitudinal follow-up of surviving patients.

Continued enrollment and dosing escalation in the CRC protocol.

Preparation for future Phase 3 studies in mTNBC and other solid tumor indications.

Presentation Details:

Poster Session: Thursday, May 15, 2025, 12:00–12:45 PM CEST

Location: Hall B0, ESMO Breast Cancer Conference, Munich, Germany

Presenter: Dr. Richard Pestell, MD, PhD, AO

Quote from Dr. Lalezari:

“The survival outcomes we are seeing, combined with the biological mechanism emerging, could represent a paradigm shift in how we think about treating advanced solid tumors.”

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 107

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 147

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 51

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 84

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 39

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 67

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 76

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading

Top 5 Most Recently Viewed Articles

CEO of Cogent Communications to Showcase Company Updates

Updated Category News Views 112

Cogent Communications' CEO Will Share Insights at Key Conferences Cogent Communications Holdings, Inc. (NASDAQ: CCOI), recognized as one of the world's premier Internet service providers, has exciting news to share. Dave Schaeffer, the Chief Executive Officer, is set to present at two significant upcoming conferences, demonstrating leadership in the connectivity space....

Continue Reading
AnteraCapital 365 Unmasked: The Truth Behind Fraudulent Claims

Updated Category News Views 338

Understanding the Fraud of AnteraCapital 365 Be an informed investor – protect yourself against fraudulent schemes. The Canadian Investment Regulatory Organization (CIRO) has issued a warning regarding AnteraCapital 365. This fraudulent firm operates on multiple websites claiming to be associated with legitimate organizations, specifically, SIG North Trading, ULC. It is...

Continue Reading
Understanding the Liberty Broadband and Charter Merger Insights

Updated Category News Views 309

Rowley Law PLLC Conducts Investigation into Liberty Broadband Recently, Rowley Law PLLC has announced an investigation related to proposed acquisition activities involving Liberty Broadband Corporation (NASDAQ: LBRDA). This scrutiny comes amid news that Charter Communications, Inc. (NASDAQ: CHTR) intends to acquire Liberty Broadband. This proposed merger is set to impact...

Continue Reading
C3.ai Investors Urged to Act Now for Class Action Lawsuit

Updated Category News Views 198

C3.ai Investors Face Class Action Lawsuit The recent developments regarding C3.ai, Inc. (NYSE: AI) are significant for investors who have faced substantial losses. The former Attorney General of Louisiana, Charles C. Foti, Jr., alongside Kahn Swick & Foti, LLC, has reached out to stakeholders, reminding them of an impending deadline related to a class action lawsuit....

Continue Reading
JW Michaels Shares Insights on Salary Trends in Finance

Updated Category News Views 311

Understanding Executive Compensation in Financial Services Every year, companies and organizations strive to understand the nuances of compensation within the financial sector. JW Michaels & Co. recently released its latest Financial Services Market Data Report, offering valuable insights into executive remuneration practices for top-tier positions. This comprehensive...

Continue Reading